ABSTRACT
BACKGROUND/AIMS: Apoptosis via Fas/FasL system is thought to be involved in the development of hepatocyte death in viral hepatitis B. In chronic hepatitis C, sFas/sFasL system was reported to control liver injury induced by Fas/FasL mediated apoptosis. To determine the role of sFas/sFasL system in chronic hepatitis B, we analyzed serum sFas/sFasL in 58 HBV patients and 29 healthy controls. METHODS: HBV patients were categorized into two groups; normal ALT (40 IU/L). Serum sFas/sFasL levels in HBV patients were measured by ELISA and was compared with those in 29 healthy controls. Serum ALT levels, histological activity, and Fas/FasL expression of liver were compared. RESULTS: Chronic hepatitis B patients with elevated ALT had significantly higher serum sFas levels than those in healthy controls (P<0.01). Serum sFasL levels, however, were significantly lower than those in healthy controls (P<0.01). Patients with moderate to marked degree of inflammation and fibrosis had significantly higher serum sFas levels than those in healthy controls (P<0.05). Serum sFasL levels had no correlation with the hepatic histological activity. Serum sFas/sFasL levels also had no significant correlation with the Fas/FasL expression of liver. CONCLUSIONS: Serum sFas/sFasL levels play a possible role in the pathogenesis of chronic hepatitis B. These results suggest that serum sFas levels might serve as a marker for estimating the degree of hepatic histological activity.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , fas Receptor/analysis , Fas Ligand Protein/analysis , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/diagnosisABSTRACT
Objective To investigate the correlation of serum sFasL level with carotid arterial intima- media thickness(IMT) and some known markers of inflammation, nutritional status in uremic patients with cardiovascular disease(CVD). Methods 134 uremic patients on hemodialysis were divided into two groups, CVD group (n=103) and non-CVD group (n=31). The serum level of sFasL, C-reactive protein (CRP), IL-6, TNF-? and albumin were measured by enzyme-linked immunosorbent assays (ELISA). The expression of Fas and FasL in radial arterial endothelial cells were observed both by immuohistochemical stain and by reverse transcription- polymerase chain reaction (RT-PCR). The Carotid arterial IMTs were measured by Color doppler ultrasonography. Results Compared with the non-CVD group, CVD group showed significantly increased serum sFasL, CRP, IL-6, and TNF-?, and decreased serum albumin(P
ABSTRACT
Objective:To investigate the role of soluble Fas ligand (sFasL) in the mechanism of immune escape and counterattack of colorectal cancer.Methods:ELISA was used to detect the level of sFasL in the sera of colorectal cancer patients and the supernatant of SW480. Transmission electron microscopy (TEM), flow cytometry (FCM) analysis and fluorescence microscopy were used to examine the apoptosis of Jurkat induced by the sera of colorectal cancer patients and the supernatant of SW480. The apoptosis was also studied after pretreatment of Jurkat by Fas blocking antibody ZB4. The supernatant of African green monkey cell line Vero was used as control.Results:The concentration of sFasL in sera of colorectal cancer patients was 12.21?1.14 ?g/L before treatment, the concentration decreased significantly after treatment(P
ABSTRACT
0. 05 ]. However, the level of sFas was significantly higher in the patients with CHF than those of the cardiac function class Ⅰ group [CHF group: 1353. 30 ? 507. 71 (cardiac function class Ⅱ 1154. 85 ? 371.20, class Ⅲ 1412. 88 ? 493. 62, class Ⅳ 1875.67 ? 806. 10) vs. cardiac function class Ⅰ group:983. 11 ? 416.26 pg/ml, P